Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00219817

Enrollment

Registered

2005-09-22

Start date

2005-06-30

Completion date

2006-10-31

Last updated

2013-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Cachexia

Keywords

Anorexia, Cachexia

Brief summary

Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.

Interventions

DRUGRC-1291 HCl

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Community-dwelling patients ≥ 18 years of age with incurable, histologically diagnosed cancer. * Involuntary loss of body weight of ≥ 5 % within the past 6 months

Exclusion criteria

* Presently hospitalized or in a nursing care facility. * Inability to increase food intake from secondary causes. * Liver disease * If female-pregnant, breast-feeding or of childbearing potential.

Design outcomes

Primary

Measure	Time frame
Body Weight	—
Lean Body Mass	—
Functional Performance	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026